Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies The SEARCH-AF study

被引:361
作者
Lowres, Nicole [1 ,2 ,3 ]
Neubeck, Lis [4 ,5 ]
Salkeld, Glenn [6 ]
Krass, Ines [7 ]
McLachlan, Andrew J. [7 ,8 ]
Redfern, Julie [3 ,4 ]
Bennett, Alexandra A. [7 ,8 ]
Briffa, Tom [9 ]
Bauman, Adrian [6 ]
Martinez, Carlos [10 ]
Wallenhorst, Christopher [10 ]
Lau, Jerrett K. [1 ]
Brieger, David B. [1 ,2 ,3 ]
Sy, Raymond W. [1 ,2 ,3 ]
Ben Freedman, S. [1 ,2 ,3 ]
机构
[1] Univ Sydney, Concord Repatriat Gen Hosp, Dept Cardiol, Sydney, NSW 2006, Australia
[2] Anzac Res Inst, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[4] George Inst Global Hlth, Sydney, NSW, Australia
[5] Univ Sydney, Sydney Nursing Sch, Sydney, NSW 2006, Australia
[6] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia
[7] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia
[8] Concord Repatriat Gen Hosp, Ctr Educ & Res Aging, Sydney, NSW, Australia
[9] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia
[10] Stat & Informat GmbH, Inst Epidemiol, Frankfurt, Germany
基金
澳大利亚国家健康与医学研究理事会;
关键词
Atrial fibrillation; screening; stroke prevention; cost-effectiveness; anticoagulation; NET CLINICAL BENEFIT; HEART-ASSOCIATION; MODELING ANALYSIS; ISCHEMIC-STROKE; BLEEDING RISK; POPULATION; DABIGATRAN; WARFARIN; APIXABAN; THERAPY;
D O I
10.1160/TH14-03-0231
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) causes a third of all strokes, but often goes undetected before stroke. Identification of unknown AF in the community and subsequent anti-thrombotic treatment could reduce stroke burden. We investigated community screening for unknown AF using an iPhone electrocardiogram (iECG) in pharmacies, and determined the cost-effectiveness of this strategy. Pharmacists performed pulse palpation and iECG recordings, with cardiologist iECG over-reading. General practitioner review/12-lead ECG was facilitated for suspected new AF. An automated AF algorithm was retrospectively applied to collected iECGs. Cost-effectiveness analysis incorporated costs of iECG screening, and treatment/outcome data from a United Kingdom cohort of 5,555 patients with incidentally detected asymptomatic AF. A total of 1,000 pharmacy customers aged >= 65 years (mean 76 +/- 7 years; 44% male) were screened. Newly identified AF was found in 1.5% (95% Cl, 0.8-2.5%); mean age 79 +/- 6 years; all had CHA(2)DS(2)-VASc score >= 2. AF prevalence was 6.7% (67/1,000). The automated iECG algorithm showed 98.5% (Cl, 92-100%) sensitivity for AF detection and 91.4% (Cl, 89-93%) specificity. The incremental cost-effectiveness ratio of extending iECG screening into the community, based on 55% warfarin prescription adherence, would be $AUD5,988 ((sic),142; $USD4,066) per Quality Adjusted Life Year gained and $AUD30,481 ((sic)15,993; $USD20,695) for preventing one stroke. Sensitivity analysis indicated cost-effectiveness improved with increased treatment adherence. Screening with iECG in pharmacies with an automated algorithm is both feasible and cost-effective. The high and largely preventable stroke/thromboembolism risk of those with newly identified AF highlights the likely benefits of community AF screening. Guideline recommendation of community iECG AF screening should be considered.
引用
收藏
页码:1167 / 1176
页数:10
相关论文
共 48 条
[1]   An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality [J].
Aliot, Etienne ;
Breithardt, Guenter ;
Brugada, Josep ;
Camm, John ;
Lip, Gregory Y. H. ;
Vardas, Panos E. ;
Wagner, Markus .
EUROPACE, 2010, 12 (05) :626-633
[2]  
American Heart Association, HALF THOS ATR FABR D
[3]   Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations) A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [J].
Anderson, Jeffrey L. ;
Halperin, Jonathan L. ;
Albert, Nancy M. ;
Bozkurt, Biykem ;
Brindis, Ralph G. ;
Curtis, Lesley H. ;
DeMets, David ;
Guyton, Robert A. ;
Hochman, Judith S. ;
Kovacs, Richard J. ;
Ohman, E. Magnus ;
Pressler, Susan J. ;
Sellke, Frank W. ;
Shen, Win-Kuang .
CIRCULATION, 2013, 127 (18) :1916-1926
[4]   Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study [J].
Banerjee, Amitava ;
Lane, Deirdre A. ;
Torp-Pedersen, Christian ;
Lip, Gregory Y. H. .
THROMBOSIS AND HAEMOSTASIS, 2012, 107 (03) :584-589
[5]   Chlamydia testing in community pharmacies: Evaluation of a feasibility pilot in south east London [J].
Baraitser, P. ;
Pearce, V. ;
Holmes, J. ;
Horne, N. ;
Boynton, P. M. .
QUALITY & SAFETY IN HEALTH CARE, 2007, 16 (04) :303-307
[6]  
Ben Freedman S, 2013, J AM COLL CARDIOL, V61, pE371
[7]  
Benrimoj Shalom I, 2004, Aust Health Rev, V28, P238
[8]   Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited A Population-Based Study [J].
Bjorck, Staffan ;
Palaszewski, Bo ;
Friberg, Leif ;
Bergfeldt, Lennart .
STROKE, 2013, 44 (11) :3103-3108
[9]   Statistical approaches to handling uncertainty in health economic evaluation [J].
Briggs, AH .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (06) :551-561
[10]   The health loss from ischemic stroke and intracerebral hemorrhage: evidence from the North East Melbourne Stroke Incidence Study (NEMESIS) [J].
Cadilhac, Dominique A. ;
Dewey, Helen M. ;
Vos, Theo ;
Carter, Rob ;
Thrift, Amanda G. .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2010, 8